Cargando…
Acute disseminated encephalomyelitis (ADEM) following COVID-19 vaccination: A systematic review
BACKGROUND: Although global vaccination against COVID-19 infection has its excellence, potential side effects are yet of concern. Several lines of evidence have proposed ADEM occurrence after SARS-CoV-2 infection. Moreover, a large number of case reports and case series have also suggested the casua...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030273/ https://www.ncbi.nlm.nih.gov/pubmed/36963124 http://dx.doi.org/10.1016/j.jocn.2023.03.008 |
_version_ | 1784910323927482368 |
---|---|
author | Nabizadeh, Fardin Noori, Maryam Rahmani, Shayan Hosseini, Helia |
author_facet | Nabizadeh, Fardin Noori, Maryam Rahmani, Shayan Hosseini, Helia |
author_sort | Nabizadeh, Fardin |
collection | PubMed |
description | BACKGROUND: Although global vaccination against COVID-19 infection has its excellence, potential side effects are yet of concern. Several lines of evidence have proposed ADEM occurrence after SARS-CoV-2 infection. Moreover, a large number of case reports and case series have also suggested the casual association between ADEM and COVID-19 vaccination. To better understand the development of ADEM following COVID-19 vaccination and its potential association, we aimed to systematically review ADEM cases reported after COVID-19 vaccination. METHODS: We conducted a comprehensive systematic search using three databases including PubMed, Scopus, and Web of Science. Studies that reported ADEM after COVID-19 vaccination were eligible to include in our study. Observational studies, case reports, and case series which reported cases of ADEM with sufficient detail to confirm clinical diagnosis following COVID-19 vaccination were eligible to enter our study. RESULTS: Twenty studies were included in our systematic review after the abstract and full-text screening with a total of 54 cases. Among included patients, 45 (85.1 %) developed ADEM after the first dose of the COVID-19 vaccine, and seven (12.9 %) cases experienced ADEM after the second dose. The median time interval between vaccination and neurological symptoms was 14 days which ranged from 12 h to 63 days. Twelve (22.2 %) patients experienced symptoms of muscle weakness, ten (18.5 %) presented unconsciousness, nine (16.6 %) patients had urinary complaints, nine (16.6 %) had visual impairments, and five (9.2 %) experienced a seizure. After treatments, four (13.8 %) patients died. Forty-six patients had clinical improvement (85.1 %), also improvement in brain MRI was observed among 44 (81.4 %) patients. CONCLUSION: In conclusion, it is not clear that ADEM could be a potential complication of COVID-19 vaccination based on the current evidence and further studies are needed. However, this rare condition should not trigger stopping the mass vaccination programs since the only way to eradicate the current pandemic of COVID-19 is to extend the number of immunized people. |
format | Online Article Text |
id | pubmed-10030273 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100302732023-03-22 Acute disseminated encephalomyelitis (ADEM) following COVID-19 vaccination: A systematic review Nabizadeh, Fardin Noori, Maryam Rahmani, Shayan Hosseini, Helia J Clin Neurosci Review Article BACKGROUND: Although global vaccination against COVID-19 infection has its excellence, potential side effects are yet of concern. Several lines of evidence have proposed ADEM occurrence after SARS-CoV-2 infection. Moreover, a large number of case reports and case series have also suggested the casual association between ADEM and COVID-19 vaccination. To better understand the development of ADEM following COVID-19 vaccination and its potential association, we aimed to systematically review ADEM cases reported after COVID-19 vaccination. METHODS: We conducted a comprehensive systematic search using three databases including PubMed, Scopus, and Web of Science. Studies that reported ADEM after COVID-19 vaccination were eligible to include in our study. Observational studies, case reports, and case series which reported cases of ADEM with sufficient detail to confirm clinical diagnosis following COVID-19 vaccination were eligible to enter our study. RESULTS: Twenty studies were included in our systematic review after the abstract and full-text screening with a total of 54 cases. Among included patients, 45 (85.1 %) developed ADEM after the first dose of the COVID-19 vaccine, and seven (12.9 %) cases experienced ADEM after the second dose. The median time interval between vaccination and neurological symptoms was 14 days which ranged from 12 h to 63 days. Twelve (22.2 %) patients experienced symptoms of muscle weakness, ten (18.5 %) presented unconsciousness, nine (16.6 %) patients had urinary complaints, nine (16.6 %) had visual impairments, and five (9.2 %) experienced a seizure. After treatments, four (13.8 %) patients died. Forty-six patients had clinical improvement (85.1 %), also improvement in brain MRI was observed among 44 (81.4 %) patients. CONCLUSION: In conclusion, it is not clear that ADEM could be a potential complication of COVID-19 vaccination based on the current evidence and further studies are needed. However, this rare condition should not trigger stopping the mass vaccination programs since the only way to eradicate the current pandemic of COVID-19 is to extend the number of immunized people. Elsevier Ltd. 2023-05 2023-03-22 /pmc/articles/PMC10030273/ /pubmed/36963124 http://dx.doi.org/10.1016/j.jocn.2023.03.008 Text en © 2023 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Article Nabizadeh, Fardin Noori, Maryam Rahmani, Shayan Hosseini, Helia Acute disseminated encephalomyelitis (ADEM) following COVID-19 vaccination: A systematic review |
title | Acute disseminated encephalomyelitis (ADEM) following COVID-19 vaccination: A systematic review |
title_full | Acute disseminated encephalomyelitis (ADEM) following COVID-19 vaccination: A systematic review |
title_fullStr | Acute disseminated encephalomyelitis (ADEM) following COVID-19 vaccination: A systematic review |
title_full_unstemmed | Acute disseminated encephalomyelitis (ADEM) following COVID-19 vaccination: A systematic review |
title_short | Acute disseminated encephalomyelitis (ADEM) following COVID-19 vaccination: A systematic review |
title_sort | acute disseminated encephalomyelitis (adem) following covid-19 vaccination: a systematic review |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030273/ https://www.ncbi.nlm.nih.gov/pubmed/36963124 http://dx.doi.org/10.1016/j.jocn.2023.03.008 |
work_keys_str_mv | AT nabizadehfardin acutedisseminatedencephalomyelitisademfollowingcovid19vaccinationasystematicreview AT noorimaryam acutedisseminatedencephalomyelitisademfollowingcovid19vaccinationasystematicreview AT rahmanishayan acutedisseminatedencephalomyelitisademfollowingcovid19vaccinationasystematicreview AT hosseinihelia acutedisseminatedencephalomyelitisademfollowingcovid19vaccinationasystematicreview |